Inventiva (IVA)
NASDAQ:IVA
Earnings Data
Report Date
Sep 23, 2026During Market Hours (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.42Last Year’s EPS
-1.62Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a constructive and execution-focused picture: major operational milestones were achieved (NATiV3 enrollment completion, >1,000 patients, clear Q4 2026 readout target), a solid near-term cash position (EUR 230.9M), conservative powering (>90%) and organizational strengthening for regulatory/commercial readiness. Key risks remain—funding beyond the stated runway depends on tranche/warrant mechanics or future financing, tolerability (weight gain/fluid retention) is a known class risk to be monitored, endpoints have inherent variability, and competition is active. On balance the call emphasized progress, readiness and a clear pathway to a potentially pivotal readout while acknowledging material clinical and financing dependencies.Company Guidance
NATiV3 Enrollment Completed
Enrollment for the global Phase III NATiV3 trial was completed in April 2025, exceeding original targets with just over 1,000 patients in the main cohort (company referenced ~1,009) plus an additional exploratory cohort of ~410 patients (F1–F4). Trial is randomized, double-blind, placebo-controlled and run over 72 weeks.
Clear Top-Line Readout Timing
Company updated top-line readout timing for NATiV3 to Q4 2026, reflecting sequencing of clinical and biostatistical milestones.
Strong Cash Position and Financing Events
As of December 31, 2025 Inventiva held EUR 230.9 million in cash, cash equivalents and short-term deposits. 2025 financing highlights include ~EUR 108 million net proceeds from the 2024 structured financing tranche and ~EUR 139.4 million net proceeds from a U.S. registered public offering.
Cash Runway Guidance
Based on current operating plan, company estimates cash runway to mid-Q1 2027 (and to mid-Q3 2027 assuming full exercise of tranche 3 warrants which could generate up to an additional EUR 116 million).
Pipeline Focus and Asset Monetization
Company strategically concentrated resources on lanifibranor for MASH in H1 2025 and sold global rights to odiparcil to Biossil in Q4 2025; potential consideration includes up to $90 million in regulatory/commercial milestones plus potential high single-digit royalties if odiparcil is approved.
Phase II Efficacy and Regulatory Designations
Lanifibranor demonstrated statistically significant improvement in the composite endpoint (fibrosis improvement and MASH resolution) in Phase IIb NATIVE; 1,200 mg dose showed a 24% treatment effect at 6 months in company commentary. FDA granted lanifibranor Breakthrough Therapy and Fast Track designations.
Trial Powering and Robust Operational Metrics
NATiV3 is powered >90% for the composite primary endpoint with the final main cohort size. The trial’s early termination/dropout rate was confirmed to be below the pre-specified 30% covenant threshold tied to prior financing tranches, leaving leadership confident the trial is well powered.
Commercial and Regulatory Readiness & Leadership Strengthening
Company strengthened leadership and commercialization/regulatory capability with hires including a CMO/President R&D (Jason Campagna), EVP Head of Quality & Regulatory Affairs (Martine Zimmermann) and Chief Commercial Strategy Officer (Nazira Amra). Pre-commercial investments increased (Marketing & BD EUR 5M) and NDA preparations are underway.
Large Addressable Market and Diagnosis Trends
Management reiterated an estimated ~18 million people in the U.S. with MASH (only ~10% diagnosed), noting diagnosis estimates grew ~25% vs. 2024. Among diagnosed patients with clinically actionable F2/F3 disease, only ~40% are currently under care, indicating substantial unmet need and growth opportunity—~375,000 patients estimated currently under care for F2/F3 in the U.S.
Differentiated Product Profile & Ancillary Benefits
Lanifibranor is a pan-PPAR designed to target hepatic and extrahepatic drivers of MASH; Phase II data showed HbA1c lowering (average ~>0.5 percentage points across population), triglyceride lowering and HDL increases—attributes management highlights as attractive for diabetic F3 patients.
IVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 30, 2026 | $5.48 | $5.55 | +1.28% |
Sep 29, 2025 | $6.05 | $5.87 | -2.98% |
Mar 26, 2025 | $2.88 | $3.04 | +5.84% |
Sep 25, 2024 | $2.17 | $1.79 | -17.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Inventiva (IVA) report earnings?
Inventiva (IVA) is schdueled to report earning on Sep 23, 2026, During Market Hours (Confirmed).
What is Inventiva (IVA) earnings time?
Inventiva (IVA) earnings time is at Sep 23, 2026, During Market Hours (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IVA EPS forecast?
IVA EPS forecast for the fiscal quarter 2026 (Q2) is -0.42.